Liguzinediol大鼠灌胃给药的绝对生物利用度  

Study on absolute bioavailability of liguzinediol in rats

作　　者：单晨啸[1] 李伟[1] 文红梅[1] 王欣之[1] 白永涛[1] 卞慧敏[1] 

机构地区：[1]南京中医药大学药学院,江苏南京210029

出　　处：《中国新药与临床杂志》2012年第11期668-671,共4页Chinese Journal of New Drugs and Clinical Remedies

基　　金：科技部"重大新药创制"科技重大专项资助项目(2009ZX09103-081);国家自然科学基金资助项目(81072542);江苏省自然科学基金资助项目(BK2008454)

摘　　要：目的研究liguzinediol在大鼠体内的药动学特征及其绝对生物利用度。方法 36只SD大鼠,♀♂各半,灌胃或尾静脉给予不同剂量liguzinediol,于不同时间点分取血浆,采用UPLC方法对血浆中liguzinediol的浓度进行测定,运用DAS 2.0药动学软件计算药动学参数及绝对生物利用度。结果灌胃给予liguzinediol高、中、低剂量(50、20、10 mg·kg^(-1))与静脉给予liguzinediol高、中、低剂量(20、10、5 mg·kg^(-1))的AUC_(0-∞)和给药剂量呈线性关系,在大鼠体内的口服绝对生物利用度大于90%。结论 Liguzinediol符合线性药动学,口服绝对生物利用度高,半衰期较短。AIM To study the pharmacokinetics characteristics of liguzinediol and its absolute bioavail- ability in rat. METHODS The plasma from 36 SD rats （half male and half female） with intragastric and intravenous administration were collected in different time point. The plasma concentration of liguzinediol was determined by UPLC. The pharmacokinetic parameters and absolute bioavailability were calculated by DAS 2.0 software. RESULTS The AUC0-∞ showed linear-relation after intragastric （50, 20, 10 mg-kg-1） and intravenous （20, 10, 5 mg-kg-1） administration. And the absolute bioavailability was higher than 90%. CONCLUSION capacity, short The pharmacokinetic study shows that liguzinediol is characterized with good oral absorption eliminate half- life, and linear pharmacokinetics, suggesting that its pharmacokinetic performances are appropriate and merit further development

关 键 词：LIGUZINEDIOL 大鼠 药动学 生物利用度 

分 类 号：R972.1[医药卫生—药品]